Exchange: NASDAQ·Updated 07:30 PM EST

TVTX News

News
all
press releases
Travere Therapeutics (NASDAQ:TVTX) Stock Price Crosses Below 200-Day Moving Average - What's Next?
Travere Therapeutics (NASDAQ:TVTX) Shares Break Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Stock Price Crosses Below 200-Day Moving Average - What's Next?
Travere Therapeutics (NASDAQ:TVTX) Shares Break Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat
More News
Zacks Research upgraded shares of Travere Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday...
MarketBeat
Travere Therapeutics, Inc. (TVTX) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript...
SeekingAlpha
Travere Therapeutics: FILSPARI Ongoing Growth Prospects Make Travere Compelling Buy...
SeekingAlpha
Aberdeen Group plc lifted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 483.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 728,295 shares of the company's stock a...
MarketBeat
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on November 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 20 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 65,520 shares of its...
Business Wire
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday...
Business Wire
The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Travere (TVTX) delivered earnings and revenue surprises of -120.00% and +16.64%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its third quarter 2026 financial results and provided a corporate update. Strong execution across our business drove another quarter of significant growth, with FILSPARI net product sales of $200 million for the quarter as we continued to...
Business Wire

Advertisement|Remove ads.